Test Price
1,000 AED✅ Home Collection Available
AML ETO t(8;21) Gene Rearrangement Quantitative MRD Monitor Test in UAE | 1000 AED | 2026 DHA Guidelines
تحليل AML ETO t(8;21) Gene Rearrangement Quantitative MRD Monitor Test في الإمارات | 1000 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971545488731.
ملخص تنفيذي: تحليل جيني كمي دقيق لمراقبة المرض المتبقي الأدنى (MRD) لسرطان الدم النقوي الحاد (AML) مع إزفاء جيني t(8;21)، بموثوقية 99.9% ووفق أحدث إرشادات هيئة الصحة بدبي.
This service strictly adheres to Federal Decree-Law No. 41 of 2024 (Art. 87) on medical liability, CDS Law 2026 for minors’ consent, and UAE Personal Data Protection Law (PDPL). Processing cycle is certified ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). All patient data is handled under advanced encryption protocols.
Clinical Overview & Test Superiority
The AML ETO t(8;21) Gene Rearrangement Quantitative MRD Monitor Test uses highly sensitive Real-Time PCR to quantify the AML1-ETO (RUNX1-RUNX1T1) fusion transcript in blood or bone marrow. This minimally invasive assay allows dynamic tracking of minimal residual disease (MRD) for patients with core-binding factor AML, aiding precise treatment de-escalation and early relapse detection. Our method outperforms conventional cytogenetics, delivering actionable results within 3 days.
| Parameter | Our Test (AML ETO MRD qPCR) | Closest Alternative (FISH/Karyotyping) |
|---|---|---|
| Analytical Sensitivity | Up to 10⁻⁴ – 10⁻⁵ (1 leukemic cell in 10,000–100,000 normal cells) | 1–5% blast threshold |
| Methodology | Real-Time Quantitative PCR (TaqMan probes, gene-specific primers) | Fluorescence in‑situ hybridization (low resolution) |
| Turnaround Time | 3 working days | 7–10 working days |
| Clinical Utility | Longitudinal MRD kinetics, relapse prediction | Diagnostic / remission status only |
Physician Insight & Safety Protocol
“As a clinical pathologist, I underscore that AML ETO MRD monitoring by qPCR requires integration with full clinical context and bone marrow morphology. A single negative result does not equate to cure, and a rising transcript level may signal molecular relapse months before hematologic reappearance. Never adjust anti‑leukemic therapy based solely on this assay.”
— Dr. PRABHAKAR REDDY, DHA License No. 61713011
⚠️ Medication Warning
Do not discontinue, modify, or skip prescribed chemotherapy, targeted therapy, or any medication without consulting your treating oncologist. Contact your medical team immediately if a dose is missed or new symptoms occur.
🚨 Patient Safety: Exclusion Criteria & ER Red Flags
- Specimen Rejection: Hemolyzed, clotted, frozen, or incorrect tube samples will not be processed.
- Transfusion Interference: Blood transfusion within 2 weeks may artificially lower MRD levels.
- Emergency Indicators: If you experience fever >38.3°C, severe bleeding, sudden bruising, or bone pain, proceed to the nearest emergency department—these may indicate disease progression or complications.
Patient FAQ & Clinical Guidance
Q: What is the purpose of the AML ETO MRD test?
A: The AML ETO MRD test quantitatively measures residual leukemia cells after treatment to detect early relapse. By tracking the fusion gene level over time, your oncologist can assess molecular remission depth and adjust therapy before clinical symptoms appear.
س: ما الغرض من اختبار AML ETO MRD؟
ج: يقيس الاختبار كمياً الخلايا السرطانية المتبقية بعد العلاج للكشف المبكر عن الانتكاس. متابعة مستويات الجين الاندماجي تسمح بتعديل الخطة العلاجية قبل ظهور الأعراض السريرية.
Q: How often should this MRD be performed?
A: MRD monitoring frequency depends on your treatment protocol, typically every 3 months during consolidation. More frequent testing (monthly) may be advised in high‑risk settings or when transcript levels are rising; your hematologist will individualize the schedule.
س: كم مرة يجب إجراء اختبار MRD؟
ج: يعتمد تكرار الفحص على بروتوكول العلاج، وعادةً كل 3 أشهر أثناء مرحلة التثبيت. قد يُوصى بفحص شهري في الحالات عالية الخطورة أو عند ارتفاع مستويات الناسخة الجينية.
Q: Can a negative MRD result mean I am cured?
A: A sustained negative MRD over several tests indicates deep molecular remission, but lifelong follow-up is needed. Late relapses can occur, and occasional monitoring even after 5 years ensures any molecular recurrence is caught early.
س: هل نتيجة MRD السلبية تعني الشفاء التام؟
ج: استمرار سلبية MRD عبر عدة فحوصات يدل على هجوع جزيئي عميق، لكن المتابعة مدى الحياة ضرورية. الانتكاس المتأخر ممكن، والمراقبة الدورية تحمي من التأخر في التدخل.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians